TE
NBIX icon

Tema ETFs’s Neurocrine Biosciences NBIX Stock Holding History

Tema ETFs’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,548
Closed -$503K – 584
2025
Q4 		$503K Sell
3,548
-110
-3% -$15.9K 0.04% 356
2025
Q3 		$514K Sell
3,658
-246
-6% -$33.3K 0.04% 371
2025
Q2 		$491K Hold
3,904
– – 0.13% 138
2025
Q1 		$432K Buy
3,904
+58
+2% +$7.35K 0.13% 119
2024
Q4 		$525K Buy
+3,846
New +$476K 0.22% 94

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tema ETFs's NBIX Position: Q1 2026 in Review

Tema ETFs sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,548 shares — an estimated $503K sold.

Tema ETFs first reported a position in NBIX in Q4 2024 and held it in 5 quarters. The position peaked at $525K in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Tema ETFs reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Tema ETFs sold 3,548 Neurocrine Biosciences shares in Q1 2026, an estimated $503K.
  • Tema ETFs first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 5 quarters.
  • Tema ETFs's Neurocrine Biosciences position peaked at $525K in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Tema ETFs's 13F filing for Q1 2026, filed 15 Apr 2026.